CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 302 enrolled
Drug / intervention
Vagifem +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02516202
NCT02516202Phase 3Completed

The Vaginal Health Trial - Effects of Vaginal Estradiol Tablet and Moisturizing Gel on Postmenopausal Vaginal Symptoms

Fred Hutchinson Cancer Center·interventional·Posted Aug 5, 2015·Updated Jul 12, 2018

In Brief

A Phase 3 clinical trial evaluating Vagifem, Replens, and 2 other interventions for Atrophy of Vagina and 2 related conditions. Completed, enrolled 302 participants across 2 sites.

Detailed Summary

This is a new application from the Menopause Strategies: Finding Lasting Answers for Symptoms and Health (MsFLASH) Clinical Trials network. Here we propose to conduct a large multicenter trial comparing two common treatments, a vaginal hormone tablet and an over-the-counter gel, with placebo to evaluate their effects on bothersome vaginal symptoms and sexual function, and to create a biorepository of specimens for future translational, mechanistic research on the etiology of vaginal symptoms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 5, 2015
Enrollment StartApr 1, 2016
Primary CompletionMay 1, 2017
Study CompletionJul 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 10.9 years ago

Interventions

Vagifemdrug

One tablet is to be inserted vaginally daily for 2 weeks, then 2 days/week for the remaining 10 weeks of the study.

Replensdevice

2.5 gm to be applied vaginally every 3 days over 12 weeks.

Placebo tabletother

Dispensed in visually identical bottle and tablet form to Vagifem.

Placebo gelother

Dispensed in visually identical tube and gel form to Replens.